Market closedNon-fractional
INmune Bio/INMB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About INmune Bio
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Ticker
INMB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boca Raton, United States
Employees
14
Website
www.inmunebio.com
INmune Bio Metrics
BasicAdvanced
$155M
Market cap
-
P/E ratio
-$1.92
EPS
1.89
Beta
-
Dividend rate
Price and volume
Market cap
$155M
Beta
1.89
Financial strength
Current ratio
1.709
Quick ratio
1.644
Long term debt to equity
1.24
Total debt to equity
27.358
Interest coverage (TTM)
-16.97%
Management effectiveness
Return on assets (TTM)
-35.53%
Return on equity (TTM)
-81.82%
Valuation
Price to revenue (TTM)
1,075.993
Price to book
4.93
Price to tangible book (TTM)
11.87
Price to free cash flow (TTM)
-7.696
Growth
Revenue change (TTM)
-47.39%
Earnings per share change (TTM)
27.70%
3-year revenue growth
105.93%
3-year earnings per share growth
19.18%
What the Analysts think about INmune Bio
Analyst Ratings
Majority rating from 3 analysts.
INmune Bio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
30.95%
Profit margin
0.00%
NaN%
INmune Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.36
-$0.48
-$0.47
-$0.61
-
Expected
-$0.40
-$0.40
-$0.44
-$0.54
-$0.63
Surprise
-9.24%
21.52%
6.82%
14.02%
-
INmune Bio News
AllArticlesVideos
![INmune Bio Inc. to Join Russell 3000® Index](https://cdn.snapi.dev/images/v1/n/w/press6-2453448.jpg)
INmune Bio Inc. to Join Russell 3000® Index
GlobeNewsWire·1 month ago
![INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/z/n/transcript22-2425747.jpg)
INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
![INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer](https://cdn.snapi.dev/images/v1/i/t/press14-2396818.jpg)
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for INmune Bio stock?
INmune Bio (INMB) has a market cap of $155M as of July 06, 2024.
What is the P/E ratio for INmune Bio stock?
The price to earnings (P/E) ratio for INmune Bio (INMB) stock is 0 as of July 06, 2024.
Does INmune Bio stock pay dividends?
No, INmune Bio (INMB) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next INmune Bio dividend payment date?
INmune Bio (INMB) stock does not pay dividends to its shareholders.
What is the beta indicator for INmune Bio?
INmune Bio (INMB) has a beta rating of 1.89. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
![Buy or sell INmune Bio stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell INmune Bio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.